

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Novartis Vaccines and Diagnostics, Inc.	09/24/2009
RECEIVING PARTY DATA	
Name:	Novartis AG
Street Address:	Lichtstrasse 35
City:	Basel
State/Country:	SWITZERLAND
Postal Code:	4056
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12449701
CORRESPONDENCE DATA	
Fax Number:	(617)871-3392
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	(510) 923-2707
Email:	lisa.nash@novartis.com
Correspondent Name:	Novartis Institutes for BioMedical Res
Address Line 1:	220 Massachusetts Avenue, 2nd Floor
Address Line 2:	NIBR Patents
Address Line 4:	Cambridge, MASSACHUSETTS 02139
ATTORNEY DOCKET NUMBER:	PAT052559-US-PCT
NAME OF SUBMITTER:	Lisa Nash
Total Attachments: 3 source=Assign#page1.tif source=Assign#page2.tif source=Assign#page3.tif	

CH \$40.00 12449701

501475533

PATENT
REEL: 025999 FRAME: 0828

ASSIGNMENT

For good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, we

Novartis Vaccines and Diagnostics, Inc.
4560 Horton Street
Emeryville, CA 94608-2916
USA

do hereby sell, assign and transfer to Novartis AG, a company organized under the laws of the Swiss Confederation, of Lichtstrasse 35, 4056 Basel, Switzerland, and its successors, assigns and legal representatives, all our right, title and interest for all countries of the world (Novartis AG hereinafter referred to as the "ASSIGNEE") in and to (1) all of our inventions and discoveries described in the patent application(s) entitled

PIM KINASE INHIBITORS AND METHODS OF THEIR USE

and filed* in the United States Patent and Trademark Office on Aug. 21, 2009 and accorded Application Number 12/449,701 and/or filed in the RO/US on March 3, 2008 and accorded International Patent Application Number PCT/US2008/055724, (2) said patent application(s), (3) all national stages of said international patent application, (4) all other patent applications in all countries and regions claiming the priority of the provisional patent application filed in the United States Patent and Trademark Office on March 1, 2007 and accorded Application Number 60/892,444 and on January 25, 2006 and accorded Application Number 61/023,777, (5) all continuations and divisions of all of said patent applications (including further continuations and divisions such as, but not limited to, continuations of continuations and continuations of divisions), ((2)-(5) hereinafter referred to collectively as "patent applications"), (6) all patents that are granted on any of said patent applications, (7) all registrations and confirmations of, and importation certificates based on, one or more of said patents and (8) all reissues, renewals and extensions of said patents, reexamination certificates issued for said patents and supplementary protection certificates based on said patents (including the right to file patent applications on said inventions and discoveries in the names of ASSIGNEE, their designees or in any or all of our names, at their election and in accordance with applicable law in all countries and regions and all rights of priority in all countries and regions for all of said patent applications under the International Convention for the Protection of Industrial Property, the Inter-American Convention relating to inventions, Patents, Designs and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory), the same to be held and enjoyed by said ASSIGNEE, their successors, assigns and legal representatives, to the full ends of the terms for which all patents therefor may be granted, as fully and entirely as the same would have been held and enjoyed by us if this sale, assignment and transfer had not been made.

*We hereby authorize ASSIGNEE and their representatives to insert in this instrument the Application Number and the filing date of said patent application when notified thereof.

And we hereby covenant and agree that we will, at any time, upon the request and at the expense of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, patent applications, patents, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates and supplementary protection certificates in ASSIGNEE, their successors, assigns or other legal representatives, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, that we will, at any time, upon the request and at the expense of

ASSIGNEE, execute all additional patent applications, applications for registration and/or confirmation of one or more of said patents, applications for certificates of importation based on one or more of said patents, applications for reissues, renewals and extensions of one or more of said patents and supplemental protection certificates based upon one or more of said patents, and that we will make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of **ASSIGNEE**, the successors, assigns or other legal representatives.

Executed this 24 day of September 2009

Novartis Vaccines and Diagnostics, Inc.

Lisa E. Alexander U.S.
Lisa E. Alexander

Case PAT032559
International Patent Application No. PCT/US2008/053724, filed March 1, 2008
U.S. Patent Application Serial No. 60/892,444, filed March 1, 2007
U.S. Patent Application Serial No. 61/023,777, filed January 25, 2008
Entitled: PK KINASE INHIBITORS AND METHODS OF THEIR USE
Assignment to Novartis AG

ACKNOWLEDGMENT

State of California }
County of Alameda } ss.

On September 24, 2009 before me, Karen A. Zielen, Notary Public personally appeared
Lisa E. ALEXANDER who proved to me on the basis of satisfactory evidence
to be the person whose name is subscribed to the within instrument and acknowledged to me that she
executed the same in her authorized capacity, and that by her signature on the instrument the person, or the
entity upon behalf of which the person acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing
paragraph is true and correct.

WITNESS my hand and official seal.



Signature: Karen A. Zielen